Compare Incyte Corporation (INCY) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Redwire Corporation — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Redwire Corporation trades at $9.43 (market cap $2.05B). The key difference: Incyte Corporation is far larger — about 11.3× Redwire Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | RDW | |
|---|---|---|
Market Cap | $23.11B | $2.05B |
Sector | Health | Technology |
52-Week High | $118.52 | $25.90 |
52-Week Low | $67.38 | $5.06 |
Enterprise Value | $19.13B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
RDW trades at $8.60, down 1.78% on the day, with a bearish technical signal despite bullish oscillators. The company reported a net loss of $226.55 million in 2025, with negative margins and cash flow from operations. Recent news highlights a record $498 million backlog and contract wins, but concerns over dilution and losses persist. The stock is near its support levels with resistance at $9.
The outlook is mixed: strong analyst buy ratings and a $19 consensus price target suggest upside, but fundamental weaknesses and cash burn pose significant risks. Investment opportunity hinges on execution improving profitability, while key risks include continued losses and competitive pressures in the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
